Vaccines slip, Dupixent climbs for Sanofi as it readies multiple launches in 2023

Sanofi is used to reporting strong Dupixent sales growth by now, but a decline in flu vaccine revenues brought an unusual twist for the drugmaker in the fourth quarter.

Sanofi's fourth-quarter vaccine sales slipped 16% to 1.7 billion euros ($1.83 billion). The decline was expected, Sanofi's vaccines head Thomas Triomphe explained on a conference call, citing a "challenging vaccination environment marked by both patient and provider fatigue."